ロード中...
Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ong...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5914042/ https://ncbi.nlm.nih.gov/pubmed/29685160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0601-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|